APOTEX CORP. for APOTEX CORP.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 19, 2018 | $160,000 | Replaced |
| 1st Quarter - Amendment | Apr 19, 2018 | $500,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Federal policy relating to inter partes review challenges of pharmaceutical and biotechnology patents.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Budget/Appropriations BUD
HR 1892, the Bipartisan Budget Act of 2018, related to the inclusion of S.974/HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act; and HR 1625, the Consolidated Appropriations Act of 2018, related to the inclusion of S.974/HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Trade (domestic/foreign) TRD
Federal policy related to the inclusion of provisions that enhance and facilitate generic drug and biosimilar competition in a revised North American Free Trade Agreement
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.